A5081885325- Lung Cancer Treatments and Mutations
- Bladder and Urothelial Cancer Treatments
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Urinary and Genital Oncology Studies
- Lung Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Multiple and Secondary Primary Cancers
- Prostate Cancer Treatment and Research
- Palliative Care and End-of-Life Issues
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Lipids, and Metabolism
- CAR-T cell therapy research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Prostate Cancer Diagnosis and Treatment
- Pituitary Gland Disorders and Treatments
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Estrogen and related hormone effects
- Pain Management and Opioid Use
- Pancreatic and Hepatic Oncology Research
- Urological Disorders and Treatments
- Inflammatory mediators and NSAID effects
Thomas Jefferson University
2019-2025
Sidney Kimmel Cancer Center
2020-2024
Thomas Jefferson University Hospital
2021-2024
Einstein Medical Center Philadelphia
2010-2022
American University of Beirut
2016
Einstein Healthcare Network
2003-2014
Brigham and Women's Hospital
2012-2014
Dana-Farber Cancer Institute
2007-2014
RTOG Foundation
1993-2014
Veterans Health Administration
2014
Multiple prospective Radiation Therapy Oncology Group (RTOG) protocols have evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive bladder cancer (MIBC), reserving cystectomy salvage treatment. We performed a pooled analysis of long-term outcomes in patients with MIBC enrolled across multiple studies.Four hundred sixty-eight were onto six RTOG bladder-preservation studies, including five phase II studies (RTOG 8802, 9506, 9706, 9906, and 0233) one III study 8903)....
Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary assessment. Critical needs include optimized multigene strategies that incorporate evolving genetic data, consistency in GT indications alternate evaluation models address the rising demand for services. A multidisciplinary consensus conference included experts, stakeholders, national organization leaders was convened response to current practice challenges develop implementation...
PURPOSE This phase II study was designed to evaluate effectiveness and toxicity of a combined chemoradiotherapy program with selective bladder preservation in the management patients invasive cancer. PATIENTS AND METHODS Ninety-one eligible cancer stages T2M0 T4AM0 suitable for radical cystectomy received two courses methotrexate, cisplatin, vinblastine (MCV regimen) followed by radiotherapy 39.6 Gy concurrent cisplatin. After complete urologic evaluation, operable who achieved response were...
The purpose of this study was to evaluate the impact carboplatin and paclitaxel in patients with advanced previously untreated thymoma thymic carcinoma.We conducted a prospective multicenter unresectable (n = 21) or carcinoma 23). Patients were treated (area under curve, 6) plus (225 mg/m(2)) every 3 weeks for maximum six cycles. primary end point trial objective response rate.From February 2001 through January 2008, 46 enrolled. Thirteen had grade 4 greater toxicity, mostly neutropenia....
To investigate differences in attitudes, preferences, and behaviors regarding end of life terminally ill patients their designated family caregivers.68 African-American white with stage III-B or IV lung colon cancer 68 patient-designated caregivers interviewed between December 1999 May 2001.White were more likely to have a durable power attorney (34% v 8%, P =.01) living will (LW; 41% 11%, =.004) than patients. More desired the use life-sustaining measures (cardiopulmonary resusitation...
Although studies have reported ethnic differences in approaches to end of life, the role spiritual beliefs is less well understood.This study investigated between African American and White patients with cancer their use spirituality cope examined coping preferences at end-of-life.The authors analyzed data from interviews 68 an advanced stage lung or colon December 1999 June 2001.Similar high percentages being "moderately very spiritual" religious." were more likely report using as compared...
The medical records of all patients treated for Hodgkin's disease during the years 1964-1981 were reviewed. Four hundred seventy-three previously untreated analyzed. Thirty-four subsequent second malignant neoplasms observed in 33 among those disease. Eight cases acute nonlymphocyctic leukemia, one case chronic myeloid three non-Hodgkin's lymphoma, sarcoma, and 19 other tumors identified. ten-year estimated risk leukemia by treatment was following: radiotherapy only (0), chemotherapy (0.02),...
Background: Epidemiologic and biochemical evidence suggest a role of statins angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as anti-neoplastic agents. This study was designed to evaluate the association between use these agents risk breast cancer recurrence. Methods: We reviewed medical records patients treated for stage II/III 1999 2005. Statin ACE-inhibitors/ARB users were defined who took medications at least 6 months in no disease (NED) after...
To compare the efficacy and safety of weekly paclitaxel in combination with carboplatin administered every 4 weeks to standard regimen 3 for treatment patients advanced non-small-cell lung cancer (NSCLC).Four hundred forty-four previously untreated stage IIIB/IV NSCLC were randomly assigned either arm 1 (n = 223), 100 mg/m(2) area under curve (AUC) 6 mg/mL x min on day each week cycle, or 2 221), 225 AUC 3-week cycle. After four cycles therapy, both arms eligible continue (70 mg/m(2), weeks)...
Bempegaldesleukin (BEMPEG) is a pegylated interleukin (IL)-2 cytokine prodrug engineered to provide controlled and sustained activation of the clinically validated IL-2 pathway, with goal preferentially activating expanding effector CD8
PURPOSE The purpose of this study was to determine the maximum-tolerated dose (MTD) fluorouracil (5-FU) administered as a protracted intravenous (IV) infusion with concurrent radiation in patients pancreaticobiliary carcinoma. METHODS Twenty-five recurrent, residual, or unresectable carcinoma pancreas biliary tract were treated on phase I trial IV infusions 5-FU, beginning at 200 mg/m2/d, therapy (59.4 Gy 33 fractions over 6 7 weeks). Chemotherapy began first day and continued through entire...
Preclinical targeting of the hedgehog pathway by vismodegib and insulin-like growth factor 1 receptor cixutumumab enhances efficacy chemotherapy also demonstrates activity against tumor cell fraction responsible for disease recurrence in small lung cancer.Patients with newly diagnosed extensive-stage cancer (SCLC-ED) were randomized to receive four 21-day cycles cisplatin etoposide alone (cisplatin at 75 mg/m(2) on day 100 days 1-3; arm A) or combination either (150 mg/d mouth; B) (6...
Purpose Appropriate therapy for Eastern Cooperative Oncology Group (ECOG) performance status (PS) -2 patients with advanced non–small-cell lung cancer (NSCLC) remains challenging. PS-2 on ECOG 1594 had a median survival (MS) of only 4.1 months and 1-year overall (OS) 19%. Three percent grade 5 toxicity. Patients Methods 1599, the first PS 2–specific, US cooperative group trial treatment-naïve NSCLC, randomly assigned to dose-attenuated carboplatin/paclitaxel (the least toxic regimen in 1594)...
Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide. While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC present locally advanced which associated 10–15% 5-year survival rate and poor overall prognosis. Muscle-invasive bladder (MIBC) about 50% 5 year when treated by radical cystectomy or trimodality therapy; stage IV survival. Current therapeutic modalities for MIBC include neoadjuvant chemotherapy, surgery and/or...
128 Background: T-cell engaging bsAbs and CAR therapy have shown exceptional success in treating multiple hematologic malignancies. More recently, been FDA-approved to treat uveal melanoma small cell lung cancer, demonstrating proof-of-concept for immune therapies beyond checkpoint inhibition effectively solid tumors. CAR-T are presently undergoing evaluation trials patients with mCRPC. Despite early successes these classes of therapy, there ongoing challenges including dose-limiting...
815 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) or chemoradiation (CRT) is the standard of care for patients (pts) with muscle invasive bladder cancer (MIBC). Mutations in DNA damage repair genes enrich pathologic downstaging after NAC. In RETAIN-1, a risk-adapted approach was employed to identify cystectomy-sparing active surveillance (AS) following NAC, reporting 73% 2-year MFS rate. RETAIN-2 employs similar but incorporates...
Abstract BACKGROUND. The purpose of this study was to compare the outcomes between elderly (aged ≥70 years) patients treated with paclitaxel on a weekly basis and carboplatin (every 4 weeks) versus standard 3‐weekly regimen for first‐line therapy advanced nonsmall cell lung cancer. METHODS. Of 444 enrolled, 136 (31%) were aged years. Seventy‐two randomized schedule (paclitaxel, 100 mg/m 2 3 weeks; carboplatin, area under curve [AUC] = 6 mg/mL·min Day 1 every weeks), 64 225 ; AUC 21 days)....